help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Widmer, U.
Right arrow Articles by Froesch, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Widmer, U.
Right arrow Articles by Froesch, E. R.

Journal of Clinical Endocrinology & Metabolism, Vol 55, 833-839, Copyright © 1982 by Endocrine Society

ARTICLES

Is extrapancreatic tumor hypoglycemia associated with elevated levels of insulin-like growth factor II?

U Widmer, J Zapf and ER Froesch

We have tried to answer the still controversial question of whether or not extrapancreatic tumor hypoglycemia is associated with elevated levels of insulin-like growth factor II (IGF II), keeping in mind that controversial results may be due to methodological differences. Serum levels of IGF II were determined by a rat liver membrane radioreceptor assay and by RIA. Serum samples were gel filtered at acidic pH, and some sera were also tested after acid-ethanol extraction as an alternative method for dissociating and separating IGF from the IGF carrier protein. Additionally, the radioreceptor assay was performed with a labeled partially purified IGF preparation [nonsuppressible insulin-like activity soluble in acid-ethanol (NSILA-s "70")] that was used by a group reporting elevated NSILA-s levels in about 40% of their patients with tumor hypoglycemia. Mean serum levels of receptor- reactive IGF II and immunoreactive IGF II (+/- SD) were 436 +/- 169 and 540 +/- 256 ng/ml in 22 patients with tumor hypoglycemia, as compared with 578 +/- 155 and 647 +/- 217 ng/ml in 28 normal adults. This pattern of slightly, but not significantly lower mean IGF II values in tumor hypoglycemia was unchanged when a less pure IGF preparation (NSILA-s 70) was used as a tracer or when the sera were extracted with acid-ethanol. Thus, hypoglycemia resulting from extrapancreatic tumors is not likely to be associated with increased receptorreactive or immunoreactive IGF II levels.


This article has been cited by other articles:


Home page
 Cancer Res.Home page
C. D. Hoang, X. Zhang, P. D. Scott, T. J. Guillaume, M. A. Maddaus, D. Yee, and R. A. Kratzke
Selective Activation of Insulin Receptor Substrate-1 and -2 in Pleural Mesothelioma Cells: Association with Distinct Malignant Phenotypes
Cancer Res., October 15, 2004; 64(20): 7479 - 7485.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. Hizuka, I. Fukuda, K. Takano, K. Asakawa-Yasumoto, Y. Okubo, and H. Demura
Serum High Molecular Weight Form of Insulin-Like Growth Factor II from Patients with Non-Islet Cell Tumor Hypoglycemia Is O-Glycosylated
J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2875 - 2877.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1982 by The Endocrine Society